Company news

Shattuck Labs, Inc. (NASDAQ:STTK) news

Shattuck Labs, Inc. news releases on 6ix. Latest, Oct 1, 2026: Shattuck Labs Announces Phase 2 Clinical Trial of SL-325 in Hidradenitis Suppurativa…

Shattuck Labs, Inc. (NASDAQ:STTK) news

Press releases & updates

Shattuck Labs Announces Phase 2 Clinical Trial of SL-325 in Hidradenitis Suppurativa and Appointment of Shoba Ravichandran, M.D., as Senior Vice President, Clinical Development

Shattuck Labs Announces Phase 2 Clinical Trial of SL-325 in Hidradenitis Suppurativa and Appointment of Shoba Ravichandran, M.D., as Senior Vice President, Clinical Development

Shattuck Labs Announces Participation in Upcoming September Investor Conferences

Shattuck Labs Reports Second Quarter 2026 Financial Results and Recent Business Highlights

Shattuck Labs, Inc. Announces Pricing of $75 Million Public Offering

Shattuck Labs, Inc. Announces Proposed Public Offering

Shattuck Labs Announces Exercise of Outstanding Common Stock Warrants and Provides Financial Update

Shattuck Labs Announces Phase 1 Results for SL-325

Shattuck Labs to Host Investor Call and Webcast on Phase 1 Clinical Data of SL-325, a Potentially First-in-Class DR3 Blocking Antibody, and Pipeline Update on June 8

Shattuck Labs Reports First Quarter 2026 Financial Results and Recent Business Highlights

Shattuck Labs Reports Fourth Quarter and Full-Year 2025 Financial Results and Recent Business Highlights

Shattuck Labs Announces Participation in Upcoming March Investor Conferences

Shattuck Labs Announces Participation in Upcoming Piper Sandler Virtual Novel Targets in Immunology Symposium

Shattuck Labs, Inc. Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Shattuck Labs to Participate in Upcoming December Investor Conferences

Shattuck Labs Reports Third Quarter 2025 Financial Results and Recent Business Highlights

Shattuck Labs Announces Participation in Upcoming Wedbush Securities Key Opinion Leader (KOL) and Company Panel

Shattuck Labs Announces Closing of up to $103 Million Private Placement and Appointments to Board of Directors

Shattuck Labs Announces IND for SL-325 Is in Effect for the Treatment of Inflammatory Bowel Disease

Shattuck Labs Reports Second Quarter 2025 Financial Results and Recent Business Highlights

Shattuck Labs Announces Oversubscribed Private Placement of Up to Approximately $103 Million

Shattuck Labs Announces Participation in Upcoming Leerink Partners Therapeutics Forum: I&I and Metabolism

Shattuck Labs Reports First Quarter 2025 Financial Results and Recent Business Highlights

Shattuck Labs Announces Participation in Upcoming 24th Annual Needham Virtual Healthcare Conference

Shattuck Labs Reports Fourth Quarter and Full-Year 2024 Financial Results and Recent Business Highlights

Shattuck Labs Announces Positive Data from the Preclinical GLP Toxicology Study of SL-325 at the 20th Congress of European Crohn’s and Colitis Organization (ECCO) in Inflammatory Bowel Diseases 2025

Shattuck Labs Announces Oral Presentation at Upcoming 20th Congress of European Crohn’s and Colitis Organization (ECCO) in Inflammatory Bowel Diseases 2025

Shattuck Labs Announces Poster Presentation at Upcoming 2025 Crohn’s and Colitis Congress

Shattuck Labs Announces Presentation at the 43rd Annual J.P. Morgan Healthcare Conference

Shattuck Labs Provides Corporate Update and Highlights Upcoming Key Milestones in 2025

Shattuck Labs Announces Participation in Upcoming December Conferences

Shattuck Labs Reports Third Quarter 2024 Financial Results and Recent Business Highlights

Shattuck Labs Provides Company Update and Announces SL-325, a First-In-Class Death Receptor 3 (DR3) Antagonist Targeting the TL1A/DR3 Signaling Pathway

Shattuck Labs Reports Second Quarter 2024 Financial Results and Recent Business Highlights

Shattuck Labs Announces Participation in Upcoming BTIG Virtual Biotechnology Conference

Shattuck Labs Announces Addition to Russell 2000® and Russell 3000® Indexes

Shattuck Labs Announces Updated Positive Interim Data from the Phase 1B Dose Expansion Clinical Trial of SL-172154 in Combination with Azacitidine (AZA) in Frontline Higher-Risk Myelodysplastic Syndromes (HR-MDS) and TP53 mutant (TP53m) Acute Myeloid ...

Shattuck Labs Announces Orphan Drug Designation Granted by the U.S. Food and Drug Administration (FDA) for SL-172154 for the Treatment of Acute Myeloid Leukemia (AML)

Shattuck Labs Reports First Quarter 2024 Financial Results and Recent Business Highlights

Shattuck Labs Announces Oral Presentation of Preclinical Data at the American Association for Cancer Research (AACR) Annual Meeting 2024

Shattuck Labs Announces Participation in Upcoming 23rd Annual Needham Virtual Healthcare Conference

Shattuck Labs Announces Appointment of Clay Siegall, Ph.D., and Kate Sasser, Ph.D., to its Board of Directors

Shattuck Labs Reports Fourth Quarter and Full-Year 2023 Financial Results and Recent Business Highlights

Shattuck Labs Enters into Strategic Collaboration and License Agreement with Ono Pharmaceutical to Generate Bifunctional Fusion Proteins for the Treatment of Autoimmune and Inflammatory Diseases

Shattuck Labs Provides Corporate Update and Highlights Upcoming Key Milestones in 2024

Shattuck Labs Announces Presentation at Upcoming 42nd Annual J.P. Morgan Healthcare Conference

Shattuck Labs Announces $50 Million Public Offering of Common Stock and Concurrent Private Placement of Pre-Funded Warrants

Shattuck Labs Announces Positive Initial Topline Data from Ongoing Phase 1 A/B Dose Expansion Clinical Trial of SL-172154 with Azacitidine in Frontline Higher-Risk Myelodysplastic Syndromes (HR-MDS) and TP53 mutant (TP53m) Acute Myeloid Leukemia (AML)...

Shattuck Labs Reports Third Quarter 2023 Financial Results and Recent Business Highlights

Shattuck Labs to Report Third-Quarter 2023 Financial Results on November 9, 2023